TMC
AXDX

Trellus Management Company’s Accelerate Diagnostics AXDX Stock Holding History

Trellus Management Company’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-6,100
Closed -$702K – 58
2018
Q4 		$702K Buy
+6,100
New +$904K 1.59% 22

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Trellus Management Company's AXDX Position: Q1 2021 in Review

Trellus Management Company sold out of Accelerate Diagnostics (AXDX) in Q1 2021, closing a stake of 3,278 shares — an estimated $249K sold.

Trellus Management Company first reported a position in AXDX in Q4 2016 and held it in 15 quarters. The position peaked at $1.6M in Q1 2019. 99 funds tracked by Wall St. Rank hold AXDX as of Q1 2021.

  • Trellus Management Company reported no remaining Accelerate Diagnostics position as of Q1 2021 after selling out during the quarter.
  • Trellus Management Company sold 3,278 Accelerate Diagnostics shares in Q1 2021, an estimated $249K.
  • Trellus Management Company first reported a position in Accelerate Diagnostics in Q4 2016 and held it in 15 quarters.
  • Trellus Management Company's Accelerate Diagnostics position peaked at $1.6M in Q1 2019.
  • 99 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2021.

Based on Trellus Management Company's 13F filing for Q1 2021, filed 3 May 2021.